Efficacy and Safety of Primary Glaucoma Device Implantation Surgery in Exfoliative Glaucoma: A Retrospective Consecutive Case Series

Table 2

Comparison of the mean MD, ECD, and number of topical antiglaucoma agents.

	Preoperative ( value)	6 months^† ( value)	12 months ( value)	24 months ( value)
MD, dB	−23.6 ± 5.3; (N/A)	−24.7 ± 5.2; (0.060)	−24.1 ± 5.2; (0.405)	−24.5 ± 4.9; (0.155)
ECD, cell/mm^2	2149 ± 479; (N/A)	2097 ± 457; (0.058)	2112 ± 416; (0.125)	2084 ± 465; (0.055)
Antiglaucoma agents	3.9 ± 0.6; (N/A)	0.7 ± 0.5; (<0.001)	0.9 ± 0.8; (<0.001)	1.1 ± 0.6; (<0.001)

Values are presented as the mean ± standard deviation unless otherwise indicated ( value). MD = mean deviation; ECD = corneal endothelial cell density; N/A = not applicable. Paired t-test; statistical significance: vs. preoperative value. Follow-up period after glaucoma device implantation.